Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Shigella flexneri 2A vaccine (Primary)
- Indications Bacillary dysentery
- Focus Pharmacodynamics; Proof of concept
- Sponsors LimmaTech Biologics
- 21 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017.
- 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2016 New trial record